Hilltop National Bank Trims Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Hilltop National Bank lowered its position in shares of Stevanato Group S.p.A. (NYSE:STVN) by 10.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,553 shares of the company’s stock after selling 540 shares during the period. Hilltop National Bank’s holdings in Stevanato Group were worth $99,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Pier Capital LLC boosted its position in Stevanato Group by 44.5% during the third quarter. Pier Capital LLC now owns 370,997 shares of the company’s stock valued at $7,420,000 after purchasing an additional 114,210 shares in the last quarter. Kensington Investment Counsel LLC purchased a new position in Stevanato Group during the third quarter valued at approximately $1,308,000. Wellington Management Group LLP raised its position in Stevanato Group by 4.5% during the third quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock valued at $53,872,000 after acquiring an additional 115,050 shares in the last quarter. Bamco Inc. NY increased its position in shares of Stevanato Group by 1.3% in the third quarter. Bamco Inc. NY now owns 1,685,181 shares of the company’s stock valued at $33,704,000 after buying an additional 21,469 shares in the last quarter. Finally, Fred Alger Management LLC increased its position in shares of Stevanato Group by 24.2% in the third quarter. Fred Alger Management LLC now owns 1,070,557 shares of the company’s stock valued at $21,411,000 after buying an additional 208,830 shares in the last quarter.

Stevanato Group Trading Down 4.3 %

NYSE:STVN opened at €22.92 ($23.39) on Friday. The stock’s 50 day moving average price is €21.24 and its 200 day moving average price is €20.21. The company has a market capitalization of $6.77 billion, a PE ratio of 48.77, a P/E/G ratio of 10.49 and a beta of 0.56. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group S.p.A. has a 52-week low of €16.56 ($16.90) and a 52-week high of €34.73 ($35.44).

Stevanato Group (NYSE:STVN) last announced its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.12) earnings per share for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €277.90 million during the quarter, compared to analysts’ expectations of €274.36 million. During the same quarter last year, the business posted $0.16 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. On average, research analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Bank of America increased their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Morgan Stanley reissued an “equal weight” rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Finally, Wolfe Research initiated coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stevanato Group currently has an average rating of “Moderate Buy” and an average target price of €28.60 ($29.18).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.